Originally published as JCO Early Release 10.1200/JCO.2005.04.3489 on July 17 2006
Journal of Clinical Oncology, Vol 24, No 23 (August 10), 2006: pp. 3735-3746
© 2006 American Society of Clinical Oncology.
Trastuzumab in Combination With Heregulin-Activated Her-2 (erbB-2) Triggers a Receptor-Enhanced Chemosensitivity Effect in the Absence of Her-2 Overexpression
Javier A. Menendez,
Inderjit Mehmi,
Ruth Lupu
From the Department of Medicine, Evanston Northwestern Healthcare Research Institute, Evanston; Department of Medicine, Northwestern University Feinberg School of Medicine; Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL
Address reprint requests to Ruth Lupu, PhD, Evanston Northwestern Healthcare Research Institute, 1001 University Place, Evanston, IL 60201; e-mail: r-lupu{at}northwestern.edu
Purpose The decision for treating breast cancer patients with trastuzumab is based on HER-2 amplification and/or overexpression.
Methods Using MCF-7 cells (Her-2 ±) engineered to overexpress heregulin (MCF-7/HRG), a ligand for the Her-2/3/4 network, we investigated whether HRG-induced transactivation of Her-2 affected breast cancer cell sensitivity to chemotherapy and whether trastuzumab trigger receptor-enhanced chemosensitivity (REC) when combined with chemotherapy without Her-2 overexpression.
Results MCF-7/HRG cells were more than 10-fold resistant to the alkylating agent cisplatin (CDDP), while trastuzumab coexposure completely reversed HRG-promoted CDDP resistance. A synergistic interaction between trastuzumab in combination with CDDP (paclitaxel or vincristine) was obtained in MCF-7/HRG cells. Trastuzumab prevented activation of the antiapoptotic and proliferative cascades and inhibited HRG-induced Her-2/3 phosphorylation. CDDP efficacy was enhanced by trastuzumab in cells expressing endogenously high levels of HRG. Conversely, trastuzumab coexposure was ineffective in enhancing chemotherapy efficacy in cells that did not secrete HRG, such as MCF-7 cells overexpressing a structural mutated HRG isoform. Therefore, trastuzumab-induced REC, in the absence of Her-2 overexpression, occurs through the kinase activity of Her-2/3. Interestingly, HRG expression in tumor biopsies from invasive breast carcinomas (n = 189) revealed that, whereas the minority (12%) of Her-2 positive tumors (n = 60; 32%) demonstrated Her-2 phosphorylation, the majority (67%) of HRG-overexpressing and Her-2 tumors (n = 57; 30%) were in active Her-2 status.
Conclusion We demonstrate that assessment of HRG expression and Her-2 activation define a particular breast cancer patient population for which trastuzumab plus CDDP or taxol are extremely efficient without Her-2 overexpression.
published online ahead of print at www.jco.org on July 17, 2006.
Supported by the Special Program for Research Excellence (P50CA89019-03) to R.L. Herceptin was provided by the Evanston Northwestern Healthcare Pharmacy (Evanston, IL).
Terms in blue are defined in the glossary, found at the end of this article and online at www.jco.org.
Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Facebook  Reddit  Technorati  Twitter What's this?
Related Editorial
- Can Trastuzumab Be Effective Against Tumors With Low HER2/Neu (ErbB2) Receptors?
Carlos L. Arteaga
JCO 2006 24: 3722-3725
[Full Text]
This article has been cited by other articles:
|
|
|
|
 
N. L. Spector and K. L. Blackwell
Understanding the Mechanisms Behind Trastuzumab Therapy for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer
J. Clin. Oncol.,
December 1, 2009;
27(34):
5838 - 5847.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. J.M. Boone, J. Bhosle, M. J. Tilby, J. A. Hartley, and D. Hochhauser
Involvement of the HER2 pathway in repair of DNA damage produced by chemotherapeutic agents
Mol. Cancer Ther.,
November 1, 2009;
8(11):
3015 - 3023.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Hoering, M. LeBlanc, and J. J. Crowley
Randomized Phase III Clinical Trial Designs for Targeted Agents
Clin. Cancer Res.,
July 15, 2008;
14(14):
4358 - 4367.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. C. Montero, R. Rodriguez-Barrueco, A. Ocana, E. Diaz-Rodriguez, A. Esparis-Ogando, and A. Pandiella
Neuregulins and Cancer
Clin. Cancer Res.,
June 1, 2008;
14(11):
3237 - 3241.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. V. Karamouzis, P. A. Konstantinopoulos, and A. G. Papavassiliou
ErbB/HER receptor family in breast cancer--the more we search the more we learn
Ann. Onc.,
May 1, 2008;
19(5):
1020 - 1021.
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Revillion, V. Lhotellier, L. Hornez, J. Bonneterre, and J.-P. Peyrat
ErbB/HER ligands in human breast cancer, and relationships with their receptors, the bio-pathological features and prognosis
Ann. Onc.,
January 1, 2008;
19(1):
73 - 80.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. V. Karamouzis, P. A. Konstantinopoulos, A. G. Papavassiliou, O. Mir, P. Berveiller, G. Pons, and C. A. Hudis
Trastuzumab -- Mechanism of Action and Use
N. Engl. J. Med.,
October 18, 2007;
357(16):
1664 - 1666.
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Nieto, F. Nawaz, R. B. Jones, E. J. Shpall, and S. Nawaz
Prognostic Significance of Overexpression and Phosphorylation of Epidermal Growth Factor Receptor (EGFR) and the Presence of Truncated EGFRvIII in Locoregionally Advanced Breast Cancer
J. Clin. Oncol.,
October 1, 2007;
25(28):
4405 - 4413.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. de Alava, A. Ocana, M. Abad, J. C. Montero, A. Esparis-Ogando, C. A. Rodriguez, A. P. Otero, T. Hernandez, J. J. Cruz, and A. Pandiella
Neuregulin Expression Modulates Clinical Response to Trastuzumab in Patients With Metastatic Breast Cancer
J. Clin. Oncol.,
July 1, 2007;
25(19):
2656 - 2663.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. A. Menendez and R. Lupu
Targeting Human Epidermal Growth Factor Receptor 2: It Is Time to Kill Kinase Death Human Epidermal Growth Factor Receptor 3
J. Clin. Oncol.,
June 10, 2007;
25(17):
2496 - 2498.
[Full Text]
[PDF]
|
|
|
|
